Aim immunotech announces encouraging translational data from phase 2 study evaluating ampligen® for the treatment of advanced recurrent ovarian cancer

Data presented at the society for immunotherapy of cancer (sitc) 38 th annual meeting longitudinal comparison of biomarkers in tumor microenvironment showed a gradual, durable response over time in t lymphotactic cxcr3 ligands and cytolytic factors phase 2 study ongoing; topline interim results expected before year end ocala, fla., nov. 08, 2023 (globe newswire) -- aim immunotech inc. (nyse american: aim) (“aim”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, today announced encouraging translational data from an ongoing phase 2 clinical trial utilizing aim's drug ampligen® in patients with platinum-sensitive advanced recurrent ovarian cancer.
AIM Ratings Summary
AIM Quant Ranking